| Medical and Health Sciences | Lifetime | 73 | US 43 | 100.00 |
| Psychology and Behavioral Sciences | 2021-2025 | 673 | US 233 | 98.26 |
| Clinical Neurology | Lifetime | 4 | US 2 | 99.98 |
| Cellular and Molecular Neuroscience | Lifetime | 63 | US 44 | 99.80 |
| Clinical Psychology | Lifetime | 341 | US 231 | 99.59 |
| Neuroscience of Neurology | Lifetime | 120 | US 49 | 99.07 |
| Rheumatology | Lifetime | 261 | US 115 | 98.92 |
| Psychiatry and Mental health | Lifetime | 313 | US 163 | 99.01 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 674 | US 361 | 97.75 |
| Pathology and Forensic Medicine | Lifetime | 662 | US 303 | 97.01 |
| Clinical Neurology | 2021-2025 | 18 | US 7 | 99.57 |
| Clinical Psychology | 2021-2025 | 225 | US 83 | 98.38 |
| Cellular and Molecular Neuroscience | 2021-2025 | 49 | US 27 | 96.10 |
| Psychiatry and Mental health | 2021-2025 | 473 | US 180 | 87.07 |
| Cognitive Neuroscience | 2021-2025 | 850 | US 357 | 81.53 |
| Neuroscience of Neurology | 2021-2025 | 296 | US 102 | 78.98 |
| Botulinum Toxin and Related Neurological Disorders | Lifetime | 1 | US 1 | 99.98 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 2 | US 1 | 99.98 |
| Genetic Neurodegenerative Diseases | Lifetime | 2 | US 1 | 99.94 |
| Neurological and metabolic disorders | Lifetime | 1 | US 1 | 99.93 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 5 | US 3 | 99.97 |
| Glycogen Storage Diseases and Myoclonus | Lifetime | 2 | US 1 | 99.91 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 1 | US 1 | 99.98 |
| Hereditary Neurological Disorders | Lifetime | 8 | US 3 | 99.55 |
| Obsessive-Compulsive Spectrum Disorders | Lifetime | 20 | US 13 | 99.61 |
| Neurological diseases and metabolism | Lifetime | 19 | US 6 | 99.61 |
| Nuclear Receptors and Signaling | Lifetime | 18 | US 13 | 99.65 |
| Autoimmune Neurological Disorders and Treatments | Lifetime | 16 | US 7 | 99.17 |
| Psychosomatic Disorders and Their Treatments | Lifetime | 57 | US 20 | 99.34 |
| RNA regulation and disease | Lifetime | 66 | US 34 | 98.96 |
| Autism Spectrum Disorder Research | Lifetime | 143 | US 90 | 99.04 |
| Genetics and Neurodevelopmental Disorders | Lifetime | 231 | US 114 | 98.65 |
| Cancer Treatment and Pharmacology | Lifetime | 367 | US 195 | 98.92 |
| Trigeminal Neuralgia and Treatments | Lifetime | 71 | US 24 | 98.46 |
| Restless Legs Syndrome Research | Lifetime | 58 | US 20 | 98.09 |
| Epilepsy research and treatment | Lifetime | 546 | US 228 | 97.68 |
| Facial Nerve Paralysis Treatment and Research | Lifetime | 278 | US 134 | 96.04 |
| Ophthalmology and Eye Disorders | Lifetime | 616 | US 261 | 95.41 |
| Transcranial Magnetic Stimulation Studies | Lifetime | 589 | US 135 | 95.72 |
| Balance, Gait, and Falls Prevention | Lifetime | 947 | US 308 | 94.08 |
| Sympathectomy and Hyperhidrosis Treatments | Lifetime | 356 | US 134 | 91.15 |
| Cerebrovascular and genetic disorders | Lifetime | 317 | US 83 | 89.11 |
| Neurology and Historical Studies | Lifetime | 322 | US 152 | 89.18 |
| Body Image and Dysmorphia Studies | Lifetime | 694 | US 281 | 87.30 |
| Botulinum Toxin and Related Neurological Disorders | 2021-2025 | 1 | US 1 | 99.70 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 4 | US 1 | 99.13 |
| Neuromodulation and Treatments for Neurological Disorders | 2021-2025 | 13 | US 4 | 99.57 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 31 | US 10 | 99.31 |
| Obsessive-Compulsive Spectrum Disorders | 2021-2025 | 27 | US 8 | 98.12 |
| Autism Spectrum Disorder Research | 2021-2025 | 337 | US 143 | 94.34 |
| Psychosomatic Disorders and Their Treatments | 2021-2025 | 364 | US 74 | 87.46 |
| Hereditary Neurological Disorders | 2021-2025 | 324 | US 55 | 75.98 |
| Body Image and Dysmorphia Studies | 2021-2025 | 298 | US 79 | 76.42 |
| Parkinson's Disease and Spinal Disorders | 2021-2025 | 130 | US 36 | 73.99 |
| Nuclear Receptors and Signaling | 2021-2025 | 575 | US 126 | 58.55 |
| Glycogen Storage Diseases and Myoclonus | 2021-2025 | 919 | US 183 | 46.19 |
